Viral Vector Production (Research-use) Market Size, Share & Trends Analysis Report By Vector Type (Adenovirus, AAV, Lentivirus), By Application, By Workflow, By End Use, By Region, And Segment Forecasts, 2021 - 2028

Viral Vector Production (Research-use) Market Size, Share & Trends Analysis Report By Vector Type (Adenovirus, AAV, Lentivirus), By Application, By Workflow, By End Use, By Region, And Segment Forecasts, 2021 - 2028

Viral Vector Production (Research-use) Market Growth & Trends

The global viral vector production (research-use) market size is expected to reach USD 3.9 billion by 2028, according to a new report by Grand View Research, Inc. The market is expected to expand at a CAGR of 18.8% from 2021 to 2028. The expanding research base for advanced therapies has primarily driven the market for research applications including preclinical, clinical, and investigational studies.

The outbreak of the COVID-19 pandemic has created lucrative opportunities for the market players, particularly in the vaccine manufacturing sector. The application of viral vectors in vaccine development against SARS-CoV-2 has witnessed remarkable growth in the fiscal year 2020. By far, the manufacturing of viral vectors for research use is impeded by a lack of production capacity to fulfill the growing market needs.

Thus, operating key stakeholders are engaged in implementing new approaches to overcome these challenges and expand production capacities. The improving ratio of clinical success to the number of clinical trials of gene and cell therapy products is a testament to the enhancing manufacturing capabilities.

Currently, several new gene therapy products are in the late stages of development and the pipeline continues to expand across the globe. The forward momentum for the advanced therapy arena is anticipated to drive investment to conduct research for the development of safe viral vectors and therapies.

Viral Vector Production (Research-use) Market Report Highlights

  • Adeno-associated virus (AAV) accounted for the largest revenue share in 2020. Proven records of non-pathogenicity are one of the important key factors boosting the adoption of this segment
  • Recently, usage of AAV is rising considerably across several therapeutic areas, consequently witnessing a significant boost in adoption rate throughout the forecast period
  • In terms of revenue share, the downstream processing segment dominated the market in 2020 owing to highly complex polishing and purification procedures of final products
  • Furthermore, the growing demand for viral vectors due to their increased adoption as therapeutics has led to an increase in the need for optimizing downstream and upstream workflows
  • This is driving investment flow in both segments, resulting in a significant share of upstream processing
  • Given the extensive efforts in COVID-19 vaccine development, the application of viral vectors in the vaccine development segment has witnessed tremendous growth, resulting in the largest revenue share of this segment in 2020
  • The research institutes segment dominated the market in terms of revenue share in 2020. The increasing involvement of scientific communities in gene and cell therapy research has driven the revenue flow in this segment
  • North America captured the maximum revenue share in 2020 with the U.S. at the forefront
  • One major factor that has contributed to the larger share of this regional market is the presence of a substantial number of centers and institutes that are engaged in the R&D of advanced therapies
  • Investments made by the federal bodies for the expansion of cell therapy research base in the region are anticipated to enhance the growth of the market in North America
  • The key market players are engaged in collaboration with pharma companies to serve their viral-vector-based research needs pertaining to advanced therapy development
Please note The /report will be delivered in 2-3 business days upon order notification.


Chapter 1 Executive Summary
1.1 Viral Production Market (for Research Use Only) Outlook
1.1.1 Market Summary
Chapter 2 Research Methodology
2.1 Information Procurement
2.2 Information or Data Analysis
2.3 Market Model
2.3.1 Market Analysis, by Vector Type
2.3.1.1 By characteristics/advantage & disadvantage
2.3.1.2 By clinical trials
2.3.1.3 By manufacturing service penetration/availability
2.3.2 Market Study, By End Use
2.3.3 Regional Analysis
Chapter 3 Market Variables, Trends, & Scope
3.1 Market Segmentation & Scope
3.2 Market Dynamics
3.2.1 Market Drivers Analysis
3.2.1.1 Robust pipeline for gene therapies and viral vector vaccines
3.2.1.2 Technological advancemnets in manufacturing vectors
3.2.1.3 Highly competitive market and various strategies undertaken by market entities
3.2.2 Market Restraint Analysis
3.2.2.1 Regulatory, scientific, and ethical challenges associated with gene therapy and viral vectors
3.2.3 Market Challenge Analysis
3.2.3.1 Production capacity challenges
3.2.3.2 Manufacturing challenges pertaining to large scale production of vectors
3.2.4 Market Opportunity Analysis
3.2.4.1 Facility expansion for cell and gene therapies
3.3 Penetration & Growth Prospect Mapping for Vector Type, 2020
3.4 Industry Analysis - Porter’s
3.5 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
3.6 Viral Vector Production Capacity & Service Mapping Analysis
3.6.1 North America: Capacity & service mapping
3.6.2 Europe: Capacity & Service Mapping
3.6.2.1 Cobra Biologics (Sweden and the U.K.)
3.6.2.2 Biovian (Finland)
3.6.2.3 Oxford Biomedica (U.K.)
3.6.2.4 Lonza Pharma & Biotech (The Netherlands)
3.6.2.5 FinVector Oy (Finland)
3.6.2.6 Fujifilm Diosynth Biotechnologies (Denmark)
3.6.2.7 Fujifilm Diosynth Biotechnologies (U.K.)
3.6.2.8 Catalent Inc. (Belgium)
3.6.2.9 Novasep (Belgium)
3.6.2.10 Exothera (Belgium)
3.6.2.11 Delphi Genetics SA (Belgium)
3.6.2.12 Yposkesi (France)
3.6.2.13 VIVEbiotech (Spain)
3.6.2.14 MolMed SpA (Italy)
3.6.2.15 Anemocyte (Italy)
3.7 COVID-19 Impact Analysis
Chapter 4 Vector Type Business Analysis
4.1 Viral Vector Production (Research-use) Market: Vector Type Movement Analysis
4.2 Adenovirus
4.2.1 Adenovirus Viral Vector Production (Research-use) Market Estimates and Forecast for Adenovirus, 2017 - 2028 (USD Million)
4.3 Retrovirus
4.3.1 Retrovirus Viral Vector Production (Research-use) Market Estimates and Forecast for Retrovirus 2017 - 2028 (USD Million)
4.4 Adeno-Associated Virus (AAV)
4.4.1 Adeno-Associated Virus (AAV)Viral Vector Production (Research-use) Market Estimates and Forecast for AAV, 2017 - 2028 (USD Million)
4.5 Lentivirus
4.5.1 Lentivirus Viral Vector Production (Research-use) Market Estimates and Forecast for lentivirus, 2017 - 2028 (USD Million)
4.6 Others
4.6.1 Other Viral Vector Production (Research-use) Market Estimates and Forecast for others, 2017 - 2028 (USD Million)
Chapter 5 Workflow Business Analysis
5.1 Viral Vector Production (Research-use) Market: Workflow Movement Analysis
5.2 Upstream Processing
5.2.1 Global Upstream Processing Market Estimates And Forecast, 2017 - 2028 (USD Million)
5.2.2 Vector amplification and expansion
5.2.2.1 Global vector amplification and expansion market estimates and forecast, 2017 - 2028 (USD Million)
5.2.3 Vector recovery/harvesting
5.2.3.1 Global vector recovery/harvesting market estimates and forecast, 2017 - 2028 (USD Million)
5.3 Downstream Processing
5.3.1 Global Downstream Processing Market Estimates And Forecast for 2017 - 2028 (USD Million)
5.3.2 Purification
5.3.2.1 Global purification market estimates and forecast, 2017 - 2028 (USD Million)
5.3.3 Fill finish
5.3.3.1 Global fill finish market estimates and forecast, 2017 - 2028 (USD Million)
Chapter 6 Application Business Analysis
6.1 Viral Vector Production (Research-use) Market: Application Movement Analysis
6.2 Gene and Cell Therapy Development
6.2.1 Viral Vector Production (Research-use) Market Estimates And Forecast for Gene and Cell Therapy Development, 2017 - 2028 (USD Million)
6.3 Vaccine Development
6.3.1 Viral Vector Production (Research-use) Market Estimates And Forecast for Vaccine development 2017 - 2028 (USD Million)
6.4 Biopharmaceutical and Pharmaceutical Discovery
6.4.1 Viral Vector Production (Research-use) Market Estimates And Forecast for Biopharmaceutical And Pharmaceutical Discovery, 2017 - 2028 (USD Million)
6.5 Biomedical Research
6.5.1 Viral Vector Production (Research-use) Market Estimates And Forecast for Biomedical Research, 2017 - 2028 (USD Million)
Chapter 7 End-Use Business Analysis
7.1 Viral Vector Production (Research-use) Market: End-use Movement Analysis
7.2 Pharmaceutical and Biopharmaceutical Companies
7.2.1 Global Viral Vector Production (Research-use) Market Estimates and Forecast for Pharmaceutical And Biopharmaceutical Companies, 2017 - 2028 (USD Million)
7.3 Research Institutes
7.3.1 Global Viral Vector Production (Research-use) Market Estimates And Forecast for Research institutes, 2017 - 2028 (USD Million)
Chapter 8 Regional Business Analysis
8.1 Viral Vector Production (Research-use) Market: Regional Movement Analysis
8.2 North America
8.2.1 North America Vector Production (Research-use) Market Estimates And Forecast, 2017 - 2028 (USD Million)
8.2.2 U.S.
8.2.2.1 U.S. viral vector production (research-use) market estimates and forecast, by vector type, 2017 - 2028 (USD Million)
8.2.2.2 U.S. viral vector production (research-use) market estimates and forecast, by workflow, 2017 - 2028 (USD Million)
8.2.2.3 U.S. viral vector production (research-use) market estimates and forecast, by application, 2017 - 2028 (USD Million)
8.2.2.4 U.S. viral vector production (research-use) market estimates and forecast, by end use, 2017 - 2028 (USD Million)
8.2.3 Canada
8.2.3.1 Canada viral vector production (research-use) market estimates and forecast, by vector type, 2017 - 2028 (USD Million)
8.2.3.2 Canada viral vector production (research-use) market estimates and forecast, by workflow, 2017 - 2028 (USD Million)
8.2.3.3 Canada viral vector production (research-use) market estimates and forecast, by application, 2017 - 2028 (USD Million)
8.2.3.4 Canada viral vector production (research-use) market estimates and forecast, by end use, 2017 - 2028 (USD Million)
8.3 Europe
8.3.1 Europe Viral Vector Production (Research-use) Market Estimates And Forecast, 2017 - 2028 (USD Million)
8.3.2 Germany
8.3.2.1 Germany viral vector production (research-use) market estimates and forecast, by vector type, 2017 - 2028 (USD Million)
8.3.2.2 Germany viral vector production (research-use) market estimates and forecast, by workflow, 2017 - 2028 (USD Million)
8.3.2.3 Germany viral vector production (research-use) market estimates and forecast, by application, 2017 - 2028 (USD Million)
8.3.2.4 Germany viral vector production (research-use) market estimates and forecast, by end use, 2017 - 2028 (USD Million)
8.3.3 U.K.
8.3.3.1 U.K. viral vector production (research-use) market estimates and forecast, by vector type, 2017 - 2028 (USD Million)
8.3.3.2 U.K. viral vector production (research-use) market estimates and forecast, by workflow, 2017 - 2028 (USD Million)
8.3.3.3 U.K. viral vector production (research-use) market estimates and forecast, by application, 2017 - 2028 (USD Million)
8.3.3.4 U.K. viral vector production (research-use) market estimates and forecast, by end use, 2017 - 2028 (USD Million)
8.3.4 France
8.3.4.1 France viral vector production (research-use) market estimates and forecast, by vector type, 2017 - 2028 (USD Million)
8.3.4.2 France viral vector production (research-use) market estimates and forecast, by workflow, 2017 - 2028 (USD Million)
8.3.4.3 France viral vector production (research-use) market estimates and forecast, by application, 2017 - 2028 (USD Million)
8.3.4.4 France viral vector production (research-use) market estimates and forecast, by end use, 2017 - 2028 (USD Million)
8.3.5 Spain
8.3.5.1 Spain viral vector production (research-use) market estimates and forecast, by vector type, 2017 - 2028 (USD Million)
8.3.5.2 Spain viral vector production (research-use) market estimates and forecast, by workflow, 2017 - 2028 (USD Million)
8.3.5.3 Spain viral vector production (research-use) market estimates and forecast, by application, 2017 - 2028 (USD Million)
8.3.5.4 Spain viral vector production (research-use) market estimates and forecast, by end use, 2017 - 2028 (USD Million)
8.3.6 Italy
8.3.6.1 Italy viral vector production (research-use) market estimates and forecast, by vector type, 2017 - 2028 (USD Million)
8.3.6.2 Italy viral vector production (research-use) market estimates and forecast, by workflow, 2017 - 2028 (USD Million)
8.3.6.3 Italy viral vector production (research-use) market estimates and forecast, by application, 2017 - 2028 (USD Million)
8.3.6.4 Italy viral vector production (research-use) market estimates and forecast, by end use, 2017 - 2028 (USD Million)
8.4 Asia Pacific
8.4.1 Viral Vector Production (Research-use) Market Estimates And Forecast, 2017 - 2028 (USD Million)
8.4.2 China
8.4.2.1 China viral vector production (research-use) market estimates and forecast, by vector type, 2017 - 2028 (USD Million)
8.4.2.2 China viral vector production (research-use) market estimates and forecast, by workflow, 2017 - 2028 (USD Million)
8.4.2.3 China viral vector production (research-use) market estimates and forecast, by application, 2017 - 2028 (USD Million)
8.4.2.4 China viral vector production (research-use) market estimates and forecast, by end use, 2017 - 2028 (USD Million)
8.4.3 Japan
8.4.3.1 Japan viral vector production (research-use) market estimates and forecast, by vector type, 2017 - 2028 (USD Million)
8.4.3.2 Japan viral vector production (research-use) market estimates and forecast, by workflow, 2017 - 2028 (USD Million)
8.4.3.3 Japan viral vector production (research-use) market estimates and forecast, by application, 2017 - 2028 (USD Million)
8.4.3.4 Japan viral vector production (research-use) market estimates and forecast, by end use, 2017 - 2028 (USD Million)
8.4.4 India
8.4.4.1 India viral vector production (research-use) market estimates and forecast, by vector type, 2017 - 2028 (USD Million)
8.4.4.2 India viral vector production (research-use) market estimates and forecast, by workflow, 2017 - 2028 (USD Million)
8.4.4.3 India viral vector production (research-use) market estimates and forecast, by application, 2017 - 2028 (USD Million)
8.4.4.4 India viral vector production (research-use) market estimates and forecast, by end use, 2017 - 2028 (USD Million)
8.4.5 South Korea
8.4.5.1 South Korea viral vector production (research-use) market estimates and forecast, by vector type, 2017 - 2028 (USD Million)
8.4.5.2 South Korea viral vector production (research-use) market estimates and forecast, by workflow, 2017 - 2028 (USD Million)
8.4.5.3 South Korea viral vector production (research-use) market estimates and forecast, by application, 2017 - 2028 (USD Million)
8.4.5.4 South Korea viral vector production (research-use) market estimates and forecast, by end use, 2017 - 2028 (USD Million)
8.4.6 Australia
8.4.6.1 Australia viral vector production (research-use) market estimates and forecast, by vector type, 2017 - 2028 (USD Million)
8.4.6.2 Australia viral vector production (research-use) market estimates and forecast, by workflow, 2017 - 2028 (USD Million)
8.4.6.3 Australia viral vector production (research-use) market estimates and forecast, by application, 2017 - 2028 (USD Million)
8.4.6.4 Australia viral vector production (research-use) market estimates and forecast, by end use, 2017 - 2028 (USD Million)
8.5 Latin America
8.5.1 Latin America Viral Vector Production (Research-use) Market Estimates And Forecast, 2017 - 2028 (USD Million)
8.5.2 Brazil
8.5.2.1 Brazil viral vector production (research-use) market estimates and forecast, by vector type, 2017 - 2028 (USD Million)
8.5.2.2 Brazil viral vector production (research-use) market estimates and forecast, by workflow, 2017 - 2028 (USD Million)
8.5.2.3 Brazil viral vector production (research-use) market estimates and forecast, by application, 2017 - 2028 (USD Million)
8.5.2.4 Brazil viral vector production (research-use) market estimates and forecast, by end use, 2017 - 2028 (USD Million)
8.5.3 Mexico
8.5.3.1 Mexico viral vector production (research-use) market estimates and forecast, by vector type, 2017 - 2028 (USD Million)
8.5.3.2 Mexico viral vector production (research-use) market estimates and forecast, by workflow, 2017 - 2028 (USD Million)
8.5.3.3 Mexico viral vector production (research-use) market estimates and forecast, by application, 2017 - 2028 (USD Million)
8.5.3.4 Mexico viral vector production (research-use) market estimates and forecast, by end use, 2017 - 2028 (USD Million)
8.6 MEA
8.6.1 MEA Viral Vector Production (Research-use) Market Estimates And Forecast, 2017 - 2028 (USD Million)
8.6.2 South Africa
8.6.2.1 South Africa viral vector production (research-use) market estimates and forecast, by vector type, 2017 - 2028 (USD Million)
8.6.2.2 South Africa viral vector production (research-use) market estimates and forecast, by workflow, 2017 - 2028 (USD Million)
8.6.2.3 South Africa viral vector production (research-use) market estimates and forecast, by application, 2017 - 2028 (USD Million)
8.6.2.4 South Africa viral vector production (research-use) market estimates and forecast, by end use, 2017 - 2028 (USD Million)
8.6.3 Saudi Arabia
8.6.3.1 Saudi Arabia viral vector production (research-use) market estimates and forecast, by vector type, 2017 - 2028 (USD Million)
8.6.3.2 Saudi Arabia viral vector production (research-use) market estimates and forecast, by workflow, 2017 - 2028 (USD Million)
8.6.3.3 Saudi Arabia viral vector production (research-use) market estimates and forecast, by application, 2017 - 2028 (USD Million)
8.6.3.4 Saudi Arabia viral vector production (research-use) market estimates and forecast, by end use, 2017 - 2028 (USD Million)
Chapter 9 Competitive Analysis
9.1 Recent Developments & Impact Analysis, by Key Market Participants
9.2 Company/Competition Categorization
9.3 Manufacturer’s Landscape
9.3.1 Distribution by Location of Manufacturing Facility
9.3.2 CDMOs Operating in China
9.3.3 Distribution by Scale of Production
9.3.4 Distribution by Location Of Manufacturing Facility, Type Of Organization, And Purpose Of Production
9.4 Vendor Landscape
9.4.1 List of Key Technology Supplier
9.4.2 List of Raw Material/Technology Distributors
9.4.2.1 Region-wise Bioprocessing Technology Distributors:
9.5 List of Companies with Portfolio Comprising Viral Vector-based Therapeutic Candidates.
9.6 List of Companies with Service Portfolio offering Viral Vector Manufacturing Services.
9.7 Key Initiatives & Strategic Alliances Analysis
9.7.1 Merger & Acquisition Deals
9.7.2 Collaborations & Partnerships
9.7.3 Business Expansion
9.7.4 Technology Collaborations
9.8 Public Companies Analysis
9.8.1 Industry Players
9.8.1.1 Takara Bio Inc.
9.8.1.2 Fujifilm Diosynth Biotechnologies
9.8.1.3 Batavia Biosciences B.V.
9.8.2 Non-Industry Players
9.8.3 Synergy Analysis: Major Deals & Strategic Alliances
9.9 Private Companies
9.9.1 List of key emerging companies
9.9.2 Market Participation Categorization (Market Operations & Weakness)
9.9.3 Strategy Framework
9.10 Company Profiles: Contract Manufacturing Organizations (CMOs)
9.10.1 Merck kgaa
9.10.1.1 Company overview
9.10.1.2 Sigma-aldrich Inc.
9.10.1.3 Financial Performance
9.10.1.4 Product benchmarking
9.10.1.5 SWOT Analysis
9.10.1.6 Operational Capacity
9.10.1.7 strategic initiatives
9.10.2 Lonza
9.10.2.1 Company overview
9.10.2.2 Financial Performance
9.10.2.3 Product benchmarking
9.10.2.4 SWOT Analysis
9.10.2.5 Operational Capacity
9.10.2.6 Srategic initiatives
9.10.3 FUJIFILM Diosynth Biotechnologies U.S.A., Inc.
9.10.3.1 Company overview
9.10.3.2 Financial Performance
9.10.3.3 Product benchmarking
9.10.3.4 SWOT Analysis
9.10.3.5 Operational Capacity
9.10.3.6 Startegic initiatives
9.10.4 Cobra Biologics Ltd.
9.10.4.1 Company overview
9.10.4.2 Product benchmarking
9.10.4.3 SWOT Analysis
9.10.4.4 Operational capacity
9.10.4.5 strategic initiatives
9.10.5 Thermofisher Scientific Inc.
9.10.5.1 Company overview
9.10.5.2 Financial Performance
9.10.5.3 Product benchmarking
9.10.5.4 SWOT analysis
9.10.5.5 Operational capacity
9.10.5.6 Startegic initiatives
9.10.6 Waisman Biomanufacturing
9.10.6.1 Company overview
9.10.6.2 Product benchmarking
9.10.6.3 Swot analysis
9.10.6.4 Operational capacity
9.10.6.5 Strategic inititaives
9.10.7 genezen laboratories
9.10.7.1 Company overview
9.10.7.2 Product benchmarking
9.10.7.3 SWOT Analysis
9.10.7.4 Operational capacity
9.10.8 YPOSKESI
9.10.8.1 Company overview
9.10.8.2 Product benchmarking
9.10.8.3 SWOT Analysis
9.10.8.4 Operational capacity
9.10.8.5 Strategic initiaves
9.10.9 Advanced BioScience Laboratories, Inc. (ABL inc.)
9.10.9.1 Company overview
9.10.9.2 Financial Performance
9.10.9.3 Product benchmarking
9.10.9.4 SWOT Analysis
9.10.9.5 Operational capacity
9.10.9.6 Strategic initiatives
9.10.10 Novasep Holding s.a.s.
9.10.10.1 Company overview
9.10.10.2 Product benchmarking
9.10.10.3 SWOT Analysis
9.10.10.4 Operational Capacity
9.10.10.5 Strategic initiatives
9.10.11 Orgenesis Biotech Israel Ltd (formerly ATVIO Biotech ltd.)
9.10.11.1 Company overview
9.10.11.2 Financial Performance
9.10.11.3 Product benchmarking
9.10.11.4 SWOT Analysis
9.10.11.5 Operational Capacity
9.10.11.6 Strategic initiatives
9.10.12 Vigene biosciences Inc.
9.10.12.1 Company overview
9.10.12.2 Product benchmarking
9.10.12.3 SWOT Analysis
9.10.12.4 Operational capacity
9.10.12.5 Startegic initiatives
9.10.13 General electric company (ge healthcare).
9.10.13.1 Company overview
9.10.13.2 Financial Performance
9.10.13.3 Product benchmarking
9.10.13.4 SWOT Analysis
9.10.13.5 Operational capacity
9.10.13.6 Strategic initiatives
9.10.14 CEVEC. pharmaceuticals gmbh
9.10.14.1 Company overview
9.10.14.2 Product benchmarking
9.10.14.3 SWOT Analysis
9.10.14.4 Operational capacity
9.10.14.5 Strategic initiatives
9.10.15 Batavia Biosciences B.v.
9.10.15.1 Company overview
9.10.15.2 Product benchmarking
9.10.15.3 SWOT Analysis
9.10.15.4 Operational capacity
9.10.15.5 Strategic initiatives
9.10.16 Biovion oy
9.10.16.1 Company overview
9.10.16.2 Product benchmarking
9.10.16.3 SWOT Analysis
9.10.16.4 Operational capacity
9.10.16.5 Strategic initiatives
9.10.17 Wuxi AppTec Co., Ltd.
9.10.17.1 Company overview
9.10.17.2 Financial Performance
9.10.17.3 Product benchmarking
9.10.17.4 SWOT Analysis
9.10.17.5 Operational capacity
9.10.17.6 Strategic initiatives
9.10.18 VGXI, Inc.
9.10.18.1 Company overview
9.10.18.2 Product benchmarking
9.10.18.3 SWOT Analysis
9.10.18.4 Operational capacity
9.10.18.5 Strategic initiatives5
9.10.19 Catalent Inc.
9.10.19.1 Company overview
9.10.19.2 Paragon Bioservices Inc.
9.10.19.3 Financial performance
9.10.19.4 Product benchmarking
9.10.19.5 SWOT Analysis
9.10.19.6 Operational capacity
9.10.19.7 Strategic initiatives
9.10.20 Miltenyi Biotec gmbh
9.10.20.1 Company overview
9.10.20.2 Lentigen technology Inc.
9.10.20.3 Product benchmarking
9.10.20.4 SWOT Analysis
9.10.20.5 Operational capacity
9.10.20.6 Strategic initiatives
9.10.21 sirion biotech gmbh.
9.10.21.1 Company overview
9.10.21.2 Product benchmarking
9.10.21.3 SWOT Analysis
9.10.21.4 Operational capacity
9.10.21.5 Strategic initiatives
9.10.22 virovek incorporation
9.10.22.1 Company overview
9.10.22.2 Product benchmarking
9.10.22.3 SWOT Analysis
9.10.22.4 Operational capacity
9.10.22.5 Strategic initiaitves
9.10.23 BioNTech IMFS GmbH
9.10.23.1 Company overview
9.10.23.2 Product benchmarking
9.10.23.3 SWOT Analysis
9.10.23.4 Operational capacity
9.10.24 VIVEbiotech s.l.
9.10.24.1 Company overview
9.10.24.2 Financial Performance
9.10.24.3 Product benchmarking
9.10.24.4 SWOT Analysis
9.10.24.5 Operational capacity
9.10.24.6 Strategic initiatives
9.10.25 creative biogene
9.10.25.1 Company overview
9.10.25.2 Product benchmarking
9.10.25.3 SWOT Analysis
9.10.26 Vibalogics GmbH
9.10.26.1 Company overview
9.10.26.2 Product benchmarking
9.10.26.3 SWOT Analysis
9.10.26.4 Operational capacity
9.10.26.5 Strategic initiatives
9.10.27 Takara Bio Inc.
9.10.27.1 Company overview
9.10.27.2 Financial Performance
9.10.27.3 Product benchmarking
9.10.27.4 SWOT Analysis
9.10.27.5 Operational capacity
9.10.27.6 Strategic initiaitves
9.11 Company Profiles: In-house Manufacturers
9.11.1 Cell and Gene Therapy Catapult
9.11.1.1 Company overview
9.11.1.2 Product benchmarking
9.11.1.3 SWOT Analysis
9.11.1.4 Operational capacity
9.11.1.5 Strategic initiatives
9.11.2 Bluebird Bio Inc.
9.11.2.1 Company overview
9.11.2.2 Financial Performance
9.11.2.3 Product benchmarking
9.11.2.4 SWOT Analysis
9.11.2.5 Operational capacity
9.11.2.6 Strategic initiatives
9.11.3 Addgene Inc.
9.11.3.1 Company overview
9.11.3.2 Product benchmarking
9.11.3.3 SWOT Analysis
9.11.3.4 Operational capacity
9.11.3.5 Strategic initiatives
9.11.4 Aldevron LLc.
9.11.4.1 Company overview
9.11.4.2 Product benchmarking
9.11.4.3 SWOT Analysis
9.11.4.4 Operational capacity
9.11.4.5 Strategic initiatives
9.11.5 Astellas Pharma, Inc.
9.11.5.1 Company overview
9.11.5.2 Audentes Therapeutics
9.11.5.3 Financial performance (Astellas Pharma Inc.)
9.11.5.4 Product benchmarking
9.11.5.5 SWOT Analysis
9.11.5.6 Operational capacity
9.11.5.7 Strategic initiatives
9.11.6 BioMarin Pharmaceutical, Inc.
9.11.6.1 Company overview
9.11.6.2 Financial Performance
9.11.6.3 Product benchmarking
9.11.6.4 SWOT Analysis
9.11.6.5 Operational capacity
9.11.6.6 Strategic initiatives
9.11.7 RegenxBio, Inc.
9.11.7.1 Company overview
9.11.7.2 Financial Performance
9.11.7.3 Product benchmarking
9.11.7.4 SWOT Analysis
9.11.7.5 Operational capacity
9.11.7.6 SWOT Analysis

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook